Efficacy and safety of natalizumab treatment for relapsing-remitting multiple sclerosis: interim results of the TYSABRI® Observational Programme in Canada

被引：0
|
作者：
Jacques, F. [1 ]
Bhan, V. [2 ]
机构：
[1] Clin Neurooutaouais, Gatineau, PQ, Canada
[2] QEII Hlth Sci Ctr, Halifax, NS, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1333
引用
收藏
页码：695 / 696
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK
    Hanna, Jerome
    Rosen, Jan Paul
    Smethurst, Caroline
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (11):
  • [2] Natalizumab for relapsing-remitting multiple sclerosis: interim data from the Ireland Tysabri Observational Program (iTOP)
    Mcguigan, C.
    Ryan, A.
    Sweeney, B.
    Murphy, S. M.
    Mccabe, D.
    Kinirons, P.
    Murphy, K.
    Hutchinson, M.
    Hanna, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 762 - 763
  • [3] Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
    Butzkueven, Helmut
    Kappos, Ludwig
    Pellegrini, Fabio
    Trojano, Maria
    Wiendl, Heinz
    Patel, Radhika N.
    Zhang, Annie
    Hotermans, Christophe
    Belachew, Shibeshih
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (11): : 1190 - 1197
  • [4] Efficacy and safety of natalizumab in relapsing-remitting multiple sclerosis: an Italian multicentre observational study
    Bucello, S.
    Sangalli, F.
    Moiola, L.
    Annovazzi, P.
    Rizzo, A.
    Radaelli, M.
    Ghezzi, A.
    Grimaldi, L.
    Martinelli, V.
    Comi, G.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S129 - S130
  • [5] Associations between baseline factors and on-treatment relapses in natalizumab-treated patients with relapsing-remitting multiple sclerosis in the TYSABRI® (natalizumab) observational programme
    Wiendl, H.
    Butzkueven, H.
    Kappos, L.
    Pellegrini, F.
    Trojano, M.
    Zhang, A.
    Belachew, S.
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 : S68 - S68
  • [6] Efficacy and safety of Natalizumab treatment for relapsing-remitting multiple sclerosis: results from a retrospective French cohort
    Beyrouti, R.
    Courtois, S.
    Penombre, E.
    Mostoufizadeh, S.
    Cohen, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 649 - 649
  • [7] Efficacy and safety of natalizumab as escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, Norman
    Kiriaki, Kollia
    Katsarava, Zaza
    Woods, Sophia
    Give, Ezinne
    Diener, H.
    [J]. NEUROLOGY, 2008, 70 (11) : A90 - A90
  • [8] Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis
    Cariccio, Veronica Lanza
    Bramanti, Placido
    Mazzon, Emanuela
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 20 : 93 - 99
  • [9] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    Doshi, Anisha
    Voysey, Zanna
    Bunting, Eva
    Malik, Muzaffar
    Rashid, Waqar
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
  • [10] Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"
    Popova, E. V.
    Brylev, L. V.
    Davydovskaya, M. V.
    [J]. ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 79 - +
12345